Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 6/20 | 0.36 |
| ▸ | CFTR | P13569 | 3/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25687420 | 1.00 | SCN9A (0.36) | SCN9ACFTRCNR2ALDH1A1L3MBTL1 | |
| SCHEMBL25687417 | 1.00 | SCN9A (0.36) | SCN9ACFTRCNR2ALDH1A1L3MBTL1 | |
| SCHEMBL25697280 | 0.87 | CFTR (0.31) | CFTR | |
| SCHEMBL25697265 | 0.87 | CFTR (0.31) | CFTR | |
| SCHEMBL25687518 | 0.87 | CFTR (0.40) | SCN9ACFTRCNR2NR3C1 | |
| SCHEMBL25687377 | 0.87 | SCN9A (0.38) | SCN9ACFTRALDH1A1L3MBTL1HPGD | |
| SCHEMBL30211296 | 0.87 | CFTR (0.40) | SCN9ACFTRCNR2NR3C1 | |
| SCHEMBL25686197 | 0.87 | CFTR (0.40) | SCN9ACFTRCNR2NR3C1 | |
| SCHEMBL30007228 | 0.87 | CFTR (0.38) | CFTRCNR2NR3C1 | |
| SCHEMBL25235693 | 0.87 | CFTR (0.38) | CFTRCNR2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203004-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| WO-2021214136-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203004-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | ACE2, SIRT7, ACE | SCN9A 3046/4885CFTR 508/4885CNR2 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.